이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Elevation Oncology 미래 성장

Future 기준 확인 0/6

Elevation Oncology 의 수익은 연간 10.5% 감소할 것으로 예상되는 반면, 연간 수익은 80.1% 로 증가할 것으로 예상됩니다. 80.1% 연간. EPS는 연간 2.5% 만큼 성장할 것으로 예상됩니다.

주요 정보

-10.5%

수익 성장률

2.5%

EPS 성장률

Biotechs 수익 성장	24.1%
매출 성장률	80.1%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	28 Jun 2024

최근 미래 성장 업데이트

Recent updates

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Sep 25

수익 및 매출 성장 예측

NasdaqGS:ELEV - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	N/A	-82	-98	-99	7
12/31/2025	N/A	-62	-60	-58	7
12/31/2024	N/A	-49	-41	-41	7
3/31/2024	N/A	-39	-49	-49	N/A
12/31/2023	N/A	-46	-56	-56	N/A
9/30/2023	N/A	-57	-62	-62	N/A
6/30/2023	N/A	-85	-93	-93	N/A
3/31/2023	N/A	-95	-88	-88	N/A
12/31/2022	N/A	-95	-86	-85	N/A
9/30/2022	N/A	-86	-77	-77	N/A
6/30/2022	N/A	-59	-40	-40	N/A
3/31/2022	N/A	-44	-35	-35	N/A
12/31/2021	N/A	-32	-30	-30	N/A
9/30/2021	N/A	-31	-25	-25	N/A
6/30/2021	N/A	-22	-22	-21	N/A
3/31/2021	N/A	-20	-20	-20	N/A
12/31/2020	N/A	-17	-12	-12	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ELEV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ELEV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ELEV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ELEV 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: ELEV 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ELEV 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Elevation Oncology 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 24% to US$6.00

Price target decreased by 19% to US$4.17

Price target decreased to US$5.17

Recent updates

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Elevation Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Elevation Oncology, Inc., Annual General Meeting, Jun 13, 2024

Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors

Elevation Oncology: Rising On News, But Not The Time To Buy

Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021

New minor risk - Share price stability

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021

Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer

New major risk - Financial position

New major risk - Shareholder dilution

Elevation Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $50.062056 million.

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Price target increased by 24% to US$6.00

Advisor notifies of intention to sell stock

Advisor notifies of intention to sell stock

Price target decreased by 19% to US$4.17

Elevation Oncology, Inc. Announces Management Changes

Price target decreased to US$5.17

Elevation Oncology GAAP EPS of -$0.86 misses by $0.07

Elevation Oncology secured $50M loan facility with K2 HealthVentures

Now 36% undervalued after recent price drop

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

Elevation Oncology, Inc. Appoints David Dornan as Chief Scientific Officer

Elevation Oncology, Inc., Annual General Meeting, Jun 17, 2022

Elevation Oncology, Inc. Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022

Less than half of directors are independent

We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Elevation Oncology, Inc. has completed an IPO in the amount of $100 million.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견